PL2361609T3 - Preparat leku drobnocząsteczkowego o przedłużonym uwalnianiu - Google Patents

Preparat leku drobnocząsteczkowego o przedłużonym uwalnianiu

Info

Publication number
PL2361609T3
PL2361609T3 PL11162857T PL11162857T PL2361609T3 PL 2361609 T3 PL2361609 T3 PL 2361609T3 PL 11162857 T PL11162857 T PL 11162857T PL 11162857 T PL11162857 T PL 11162857T PL 2361609 T3 PL2361609 T3 PL 2361609T3
Authority
PL
Poland
Prior art keywords
small molecule
sustained release
drug formulation
molecule drug
release small
Prior art date
Application number
PL11162857T
Other languages
English (en)
Inventor
Andrew S Luk
Gunjan Junnarkar
Guohua Chen
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37906769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2361609(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Durect Corp filed Critical Durect Corp
Publication of PL2361609T3 publication Critical patent/PL2361609T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1213—Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11162857T 2005-09-30 2006-09-28 Preparat leku drobnocząsteczkowego o przedłużonym uwalnianiu PL2361609T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72284505P 2005-09-30 2005-09-30
EP06825283A EP1940351B1 (en) 2005-09-30 2006-09-28 Sustained release small molecule drug formulation
EP11162857.4A EP2361609B1 (en) 2005-09-30 2006-09-28 Sustained release small molecule drug formulation

Publications (1)

Publication Number Publication Date
PL2361609T3 true PL2361609T3 (pl) 2013-10-31

Family

ID=37906769

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11162857T PL2361609T3 (pl) 2005-09-30 2006-09-28 Preparat leku drobnocząsteczkowego o przedłużonym uwalnianiu

Country Status (14)

Country Link
US (6) US8852638B2 (pl)
EP (2) EP1940351B1 (pl)
JP (3) JP2009510116A (pl)
CN (1) CN101365423B (pl)
AR (1) AR056554A1 (pl)
AT (1) ATE551989T1 (pl)
AU (1) AU2006299657B2 (pl)
CA (1) CA2624088C (pl)
DK (2) DK2361609T3 (pl)
ES (2) ES2385384T3 (pl)
IL (1) IL190499A (pl)
PL (1) PL2361609T3 (pl)
TW (1) TW200803920A (pl)
WO (1) WO2007041410A2 (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
KR20040058101A (ko) * 2001-11-14 2004-07-03 알자 코포레이션 카테터 주입가능한 데포 조성물 및 그의 용도
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
EP1909689A4 (en) * 2005-07-18 2011-11-16 Univ Pennsylvania PHARMACEUTICAL IMPLANTS AND METHOD OF USE THEREOF
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
DK2167039T3 (en) 2007-05-18 2017-01-09 Durect Corp Improved depot formulations
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US8470360B2 (en) 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
EP2529757B1 (en) * 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
LT2394664T (lt) * 2010-05-31 2016-09-26 Laboratorios Farmaceuticos Rovi, S.A. Antipsichozinė injekcinė depozitinė kompozicija
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
DE102013011399A1 (de) 2012-07-31 2014-02-06 Amw Gmbh Implantat mit Risperidon
HK1220628A1 (zh) 2013-03-11 2017-05-12 Durect Corporation 包含高粘度液体载体的可注射控制释放组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
LT3137081T (lt) 2014-04-28 2018-02-26 Orphomed, Inc. Buprenorfino dimeras ir jo naudojimas gydant virškinamojo trakto sutrikimus
CN104288091B (zh) * 2014-05-30 2017-04-19 河南科技大学 一种利培酮纳米混悬温敏凝胶剂及其制备方法
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
CN104398474A (zh) * 2014-11-21 2015-03-11 内蒙古医科大学附属医院 一种利培酮鼻用凝胶剂及其制备方法
CA2998504C (en) 2015-09-21 2023-06-20 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
EP4374861A3 (en) 2015-11-16 2024-08-07 MedinCell S.A. A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
CN105542480B (zh) * 2016-03-07 2018-04-17 山东理工大学 一种用聚己内酯与p(cpp‑sa)‑聚乙二醇改进聚乙烯醇膜耐水性及柔顺性的方法
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
KR20190025635A (ko) 2016-06-30 2019-03-11 듀렉트 코퍼레이션 데포 제형
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
US11752099B2 (en) * 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
MX2020006188A (es) 2017-12-18 2020-09-17 Foresee Pharmaceuticals Co Ltd Composiciones farmaceuticas que tienen una duracion de liberacion seleccionada.
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
WO2020154315A1 (en) * 2019-01-22 2020-07-30 Indivior Uk Limited Methods for treating schizophrenia
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
US10813882B1 (en) * 2019-11-25 2020-10-27 King Abdulaziz University In situ gelling formulation for reduced initial drug burst
WO2021237039A1 (en) * 2020-05-21 2021-11-25 Veru Inc. Compositions and methods for long term release of gonadotropin-releasing hormone (gnrh) antagonists
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
US12594236B2 (en) 2021-07-16 2026-04-07 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
AU2023281232A1 (en) 2022-05-18 2024-10-24 Laboratorios Farmacéuticos Rovi, S.A. Prolonged-release injectable compositions for use in treatment with risperidone together with cyp2d6 enzyme inhibitors

Family Cites Families (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB806876A (en) 1956-02-16 1959-01-07 Wellcome Found Improvements in and relating to disposable hypodermic injection devices
GB873526A (en) 1957-08-14 1961-07-26 Upjohn Co Fluid compositions comprising (acetyl-salicylic acid)-anhydride
GB887872A (en) 1958-06-25 1962-01-24 Upjohn Co Improvements in or relating to pharmaceutical preparations
DE1467938C3 (de) 1964-05-22 1973-12-20 F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) Wasserdispergierbares Arzneipräparat für Tiere
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4891225A (en) 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4534974A (en) 1984-07-31 1985-08-13 Carter-Wallace, Inc. Pharmaceutical compositions with codeine
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
GB8522453D0 (en) 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
JPS62298530A (ja) 1986-06-16 1987-12-25 Otsuka Pharmaceut Co Ltd 坐薬用医薬組成物
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
CA2002299A1 (en) 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5026556A (en) 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
DE3927113C2 (de) 1989-08-17 1993-11-25 Dolorgiet Gmbh & Co Kg Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung
US5096715A (en) 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
US5660851A (en) 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
ES2117642T3 (es) 1990-05-10 1998-08-16 Bechgaard Int Res Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
JPH0456736A (ja) 1990-06-22 1992-02-24 Ngk Insulators Ltd 金属溶湯用フィルターカートリッジ
JPH0456736U (pl) 1990-09-14 1992-05-15
US5149543A (en) 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
WO1992014442A1 (en) 1991-02-18 1992-09-03 Commonwealth Scientific And Industrial Research Organisation Composition for use in transdermal administration
JP2907624B2 (ja) 1991-02-28 1999-06-21 株式会社日本触媒 新規含フッ素フタロシアニン化合物、その製造方法、およびそれらを含んでなる近赤外線吸収材料
JP3145742B2 (ja) 1991-09-19 2001-03-12 日東電工株式会社 ゴム系感圧性接着剤とその接着シ―ト
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
WO1993023019A1 (en) 1992-05-11 1993-11-25 Sri International Transdermal drug delivery systems and related compositions and methods of use
CA2148823C (en) * 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
NZ260909A (en) 1993-07-05 1995-04-27 Takeda Chemical Industries Ltd Production of sustained release preparation by allowing a water-soluble polypeptide to permeate into a biodegradable matrix in an aqueous solution
US5643605A (en) 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
CN1074923C (zh) * 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
CA2474701C (en) 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
ATE317690T1 (de) 1994-04-08 2006-03-15 Qlt Usa Inc Flüssige zusammensetzungen zur arzneistoffabgabe
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
WO1996021427A1 (en) 1995-01-09 1996-07-18 Atrix Laboratories, Inc. Liquid polymer delivery system
JP3274579B2 (ja) 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
PT1006935E (pt) 1995-06-07 2005-06-30 Durect Corp Sistema de entrega controlada liquido de alta viscosidade
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
ATE223206T1 (de) 1996-05-07 2002-09-15 Alkermes Inc Verfahren zur herstellung von mikropartikeln
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
JP4346696B2 (ja) 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
CN1191824C (zh) 1996-06-17 2005-03-09 詹森药业有限公司 双面凸的迅速崩解剂型
ATE203157T1 (de) 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
DE19701912C1 (de) 1997-01-10 1998-05-14 Jenapharm Gmbh Injizierbares Implantat
US5948787A (en) 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
IT1292396B1 (it) 1997-06-23 1999-02-08 Lisapharma Spa Cerotto dermico avente elevata resistenza meccanica,flessibilita' trasparenza e conducibilita' elettrica nel trattamento di affezioni
AU3273497A (en) 1997-06-23 1999-01-04 Marco Cecchini Inhaling device
US6622036B1 (en) 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
DE69916911T2 (de) 1998-02-10 2005-04-21 Gen Electric Brenner mit gleichmässiger Brennstoff/Luft Vormischung zur emissionsarmen Verbrennung
ES2359973T3 (es) 1998-03-19 2011-05-30 MERCK SHARP & DOHME CORP. Composiciones poliméricas líquidas para la liberación controlada de sustancias bioactivas.
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6703047B2 (en) 2001-02-02 2004-03-09 Incept Llc Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
DE19923551A1 (de) 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
DE50112157D1 (de) 2000-01-11 2007-04-19 Roland Bodmeier Kit zur implantation enthaltend eine trägerphase und ein lösungsmittel
KR100393478B1 (ko) 2000-03-29 2003-08-06 주식회사종근당 자가유화 매트릭스형 경점막·경피흡수제제
WO2001085731A1 (en) 2000-05-05 2001-11-15 Rpg Life Sciences Limited A PROCESS FOR THE PREPARATION OF ANTI-PSCHOTIC 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2,-a]pyrimidin-4-one
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
WO2002000137A1 (en) 2000-06-28 2002-01-03 Shukla Atul J Biodegradable vehicles and delivery systems of biologically active substances
DE10035889A1 (de) 2000-07-24 2002-02-14 Lohmann Therapie Syst Lts Medizinischer Haftkleber mit einem Gehalt an Zucker-Estern
KR100818875B1 (ko) 2000-08-14 2008-04-01 테바 파마슈티컬 인더스트리즈 리미티드 리스페리돈의 제조
DE10044545A1 (de) 2000-09-05 2002-04-04 Roland Bodmeier Retardpartikeldispersion
IT250575Y1 (it) 2000-10-10 2003-09-24 Gimatic Spa Sistema di guida registrabile per griffe di pinze azionate da unfluido
WO2002038185A2 (en) 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
CA2429898C (en) 2000-11-16 2011-02-22 Durect Corporation Devices and methods for cholesterol management
DK1372729T3 (da) 2001-02-23 2009-06-22 Genentech Inc Nedbrydelige polymere til injektion
US20040018238A1 (en) * 2001-02-26 2004-01-29 Shukla Atul J Biodegradable vehicles and delivery systems of biolgically active substances
CA2440387A1 (en) 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
GB0112324D0 (en) 2001-05-21 2001-07-11 Croda Int Plc Compounds
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
JP2003063954A (ja) 2001-08-24 2003-03-05 Saitama Daiichi Seiyaku Kk リザーバー型貼付剤
KR20040058101A (ko) 2001-11-14 2004-07-03 알자 코포레이션 카테터 주입가능한 데포 조성물 및 그의 용도
NZ533434A (en) 2001-11-14 2006-11-30 Alza Corp Thixotropic gel composition for injectable deposition
EP1446100B1 (en) 2001-11-14 2011-05-04 Durect Corporation Injectable depot compositions and uses thereof
US20040258731A1 (en) 2001-11-21 2004-12-23 Tsuyoshi Shimoboji Preparation approriate for cartilage tissue formation
BRPI0308360B8 (pt) 2002-03-12 2021-05-25 Ethypharm Sa composição termossensível sob forma liquida compreendendo substância organogelificante, utilização de uma composição e processo de preparação de uma composição
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
TWI314464B (en) 2002-06-24 2009-09-11 Alza Corp Reusable, spring driven autoinjector
TWI353854B (en) 2002-06-25 2011-12-11 Alza Corp Short duration depot formulations
WO2004011065A1 (en) 2002-07-31 2004-02-05 Alza Corporation Injection device providing automatic needle retraction
DE60325742D1 (de) 2002-07-31 2009-02-26 Alza Corp Injizierbare multimodale polymere depotzusammensetzungen und ihre verwendungen
WO2004020439A2 (en) 2002-08-30 2004-03-11 Sunil Sadanand Nadkarni Improved process for preparation of risperidone
US20040105778A1 (en) 2002-10-04 2004-06-03 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
KR20040034996A (ko) 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
RU2310450C2 (ru) 2002-10-25 2007-11-20 Пфайзер Продактс Инк. Новые депо-препараты для инъекций
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
ATE418323T1 (de) 2002-11-06 2009-01-15 Alza Corp Depot-formulierungen mit verzögerter freisetzung
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
US7501113B2 (en) 2003-02-04 2009-03-10 Philip Morris Usa Inc. Aerosol formulations and aerosol delivery of buprenorphine
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
WO2004094415A1 (en) 2003-04-22 2004-11-04 Synthon B.V. Risperidone monohydrochloride
MXPA05013003A (es) 2003-05-30 2006-03-17 Alza Corp Composiciones de deposito elastomerico implantables, usos de las mismas y metodo para elaboracion.
JP5229768B2 (ja) 2003-06-26 2013-07-03 シヴィダ・ユーエス・インコーポレイテッド Ｉｎ−Ｓｉｔｕゲル化薬物輸送システム
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
FI20045223A7 (fi) 2004-06-15 2005-12-16 Bioretec Oy Monitoiminen biohajoava komposiitti ja kirurginen implantti, joka käsittää mainitun komposiitin
US20050032781A1 (en) 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
CA2546482A1 (en) 2003-09-01 2005-03-10 F H Faulding & Co Limited Compositions and methods for delivery of biologically active agents
WO2005037949A2 (en) 2003-10-07 2005-04-28 Chrysalis Technologies Incorporated Aerosol formulations of butalbital, lorazepam, ipratropium, baclofen, morphine and scopolamine
WO2005117830A1 (en) 2004-06-04 2005-12-15 Camurus Ab Liquid depot formulations
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
JP4610567B2 (ja) 2003-12-05 2011-01-12 ゾゲニクス インコーポレーティッド 無針注射器の送達準備器具
JP2007517042A (ja) 2003-12-30 2007-06-28 デュレクト コーポレーション 活性物質、好ましくはｇｎｒｈの制御放出のための、好ましくはｐｅｇおよびｐｌｇの混合物を含有するポリマーインプラント
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
CA2553254C (en) 2004-01-12 2013-12-17 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
EP1729676A1 (en) 2004-03-15 2006-12-13 Durect Corporation Pharmaceutical compositions for administration to a sinus
IS7290A (is) 2004-05-28 2005-11-29 Actavis Group Lyfjasamsetningar sem innihalda risperidone
EP1604693A1 (en) 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
BRPI0516308A2 (pt) 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
US8246977B2 (en) 2004-10-21 2012-08-21 Durect Corporation Transdermal delivery systems
CA2586846C (en) 2004-11-10 2013-12-31 Qlt Usa Inc. A stabilized polymeric delivery system
GB2420976B (en) 2004-11-19 2006-12-20 Zvi Finkelstein Therapeutic implant
TWI369218B (en) 2004-12-14 2012-08-01 Novartis Ag In situ forming implant for animals
AU2005316545A1 (en) 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
WO2006063430A1 (en) 2004-12-16 2006-06-22 Miv Therapeutics Inc. Multi-layer drug delivery device and method of manufacturing same
US9415034B2 (en) 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
NZ565049A (en) 2005-06-17 2012-02-24 Vital Health Sciences Pty Ltd A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
EP1909689A4 (en) 2005-07-18 2011-11-16 Univ Pennsylvania PHARMACEUTICAL IMPLANTS AND METHOD OF USE THEREOF
US20070020186A1 (en) 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
EP1912627B1 (en) 2005-08-11 2016-08-10 Promedon S.A. Composition comprising polymeric, water-insoluble, anionic particles, processes and uses
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CA2627292C (en) 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
MX2008009125A (es) 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
CN105168186A (zh) 2006-10-02 2015-12-23 Apr应用制药研究股份公司 非粘膜粘着性膜剂型
MX2009003737A (es) 2006-10-05 2009-06-16 Panacea Biotec Ltd Composicion inyectable en deposito y su procedimiento de preparacion.
SI2079767T1 (sl) 2006-10-11 2015-01-30 Tolmar Therapeutics, Inc. Priprava biorazgradljivih poliestrov, ki imajo lastnost majhnega izbruha, s superkritično tekočinsko ekstrakcijo
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
GB0620661D0 (en) 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
HUE025842T2 (en) 2007-02-15 2016-04-28 Tolmar Therapeutics Inc Poly (lactide / glycolide) with reduced fracture properties and methods for producing polymers
CA2679316C (en) 2007-03-02 2016-11-29 Teika Pharmaceutical Co., Ltd. Morphine composition for transdermal absorption, morphine composition storing unit and transdermal absorption preparation using the same
BRPI0809995A2 (pt) 2007-04-03 2015-07-21 Trimeris Inc Composição, e, métodos para a liberação prolongada de um peptídeo em um paciente e para melhorar um sintoma associado com uma infecção por hiv
DK2167039T3 (en) 2007-05-18 2017-01-09 Durect Corp Improved depot formulations
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
AU2008296971B2 (en) 2007-09-03 2014-10-02 Nanoshift, Llc Particulate compositions for delivery of poorly soluble drugs
SI2200588T1 (sl) 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
JP2011506319A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
FR2926996B1 (fr) 2008-01-31 2013-06-21 Ethypharm Sa Composition pharmaceutique a proprietes gelifiantes contenant un derive de tyrosine
WO2009100222A1 (en) 2008-02-08 2009-08-13 Qps Llc Non-polymeric compositions for controlled drug delivery
CN102231981A (zh) 2008-02-08 2011-11-02 昌达生物科技公司 蛋白质或肽的缓释给药组合物
JP5286850B2 (ja) 2008-03-14 2013-09-11 大日本印刷株式会社 液体用紙容器用包装材料およびその包装材料から製造される液体用紙容器
EP2254561A2 (en) 2008-03-26 2010-12-01 AllTranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
CN102112107A (zh) 2008-06-03 2011-06-29 托马医疗科技公司 具有改进的释放动力学特征的控制释放共聚物制剂
EP2291174B1 (en) 2008-06-03 2015-01-28 Tolmar Therapeutics, Inc. Flowable composition comprising biocompatible oligomer-polymer compositions
US8128951B2 (en) 2008-09-15 2012-03-06 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8114429B2 (en) 2008-09-15 2012-02-14 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) 2008-09-15 2012-09-04 Cv Ingenuity Corp. Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
JP2012524771A (ja) 2009-04-23 2012-10-18 ロンドンファーマ リミテッド 中性油を含む舌下用の医薬組成物
JP5845172B2 (ja) 2009-05-01 2016-01-20 アデア ファーマスーティカルズ，インコーポレイテッド 高および低用量薬物の組み合わせを含む口腔内崩壊錠組成物
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
ME03396B (me) 2009-11-18 2020-01-20 Nektar Therapeutics Oblici kisele soli konjugata polimer-lek
US20130023553A1 (en) 2010-01-12 2013-01-24 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
MX343499B (es) 2010-03-15 2016-11-08 Ipsen Pharma Sas Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento.
US20110230816A1 (en) 2010-03-18 2011-09-22 Tyco Healthcare Group Lp Gels for Transdermal Delivery
LT2394664T (lt) 2010-05-31 2016-09-26 Laboratorios Farmaceuticos Rovi, S.A. Antipsichozinė injekcinė depozitinė kompozicija
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
EP2585092A1 (en) 2010-06-24 2013-05-01 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
ME02367B (me) 2010-09-21 2016-06-20 Purdue Pharma Lp Analozi buprenorfina kao agonisti i/ili antagonisti opioidnog receptora
CN103200944B (zh) 2010-11-17 2016-05-04 赫克萨尔股份公司 包含丁丙诺啡的经皮治疗系统
JP2013543898A (ja) 2010-11-24 2013-12-09 デュレクト コーポレイション 生体分解性薬物送達組成物
WO2012070027A1 (en) 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg A drug delivery device
LT2529756T (lt) 2011-05-31 2021-07-26 Laboratorios Farmaceuticos Rovi, S.A. Risperidono ir (arba) paliperidono implantų kompozicija
TW201338813A (zh) 2011-12-12 2013-10-01 洛曼治療系統股份有限公司 經皮遞送系統
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US20140134261A1 (en) 2012-08-21 2014-05-15 Trinity Laboratories, Inc. Pharmaceutical Compositions Comprising Capsaicin Esters for Treating Pain and Cold Sores
RU2513514C1 (ru) 2012-11-23 2014-04-20 Общество с ограниченной ответственностью "НПК "Трифарма" Фармацевтическая композиция, содержащая налбуфина гидрохлорид, ее применение для лечения болевого синдрома средней и высокой интенсивности и способ получения фармацевтической композиции
CN103142458B (zh) 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
HK1220628A1 (zh) 2013-03-11 2017-05-12 Durect Corporation 包含高粘度液体载体的可注射控制释放组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
IN2013MU03658A (pl) 2013-11-21 2015-09-25 Akanksha Bindeshwari Prasad Yadav
US10525171B2 (en) 2014-01-24 2020-01-07 The Spectranetics Corporation Coatings for medical devices

Also Published As

Publication number Publication date
US9044450B2 (en) 2015-06-02
ES2385384T3 (es) 2012-07-24
AR056554A1 (es) 2007-10-10
US11110093B2 (en) 2021-09-07
DK2361609T3 (da) 2013-08-26
US8852638B2 (en) 2014-10-07
JP5934685B2 (ja) 2016-06-15
AU2006299657A1 (en) 2007-04-12
US20150231258A1 (en) 2015-08-20
CA2624088C (en) 2016-03-08
JP2009510116A (ja) 2009-03-12
JP6216364B2 (ja) 2017-10-18
EP1940351A2 (en) 2008-07-09
EP1940351B1 (en) 2012-04-04
US20170239252A1 (en) 2017-08-24
CN101365423B (zh) 2012-11-21
CN101365423A (zh) 2009-02-11
AU2006299657B2 (en) 2013-03-21
US20070077304A1 (en) 2007-04-05
IL190499A (en) 2016-04-21
JP2016128411A (ja) 2016-07-14
US20200046704A1 (en) 2020-02-13
WO2007041410A2 (en) 2007-04-12
US20140086990A1 (en) 2014-03-27
TW200803920A (en) 2008-01-16
US10406160B2 (en) 2019-09-10
ES2422681T3 (es) 2013-09-13
IL190499A0 (en) 2008-11-03
US9597402B2 (en) 2017-03-21
EP2361609A1 (en) 2011-08-31
EP2361609B1 (en) 2013-07-17
WO2007041410A3 (en) 2007-07-12
US10058554B2 (en) 2018-08-28
US20180325905A1 (en) 2018-11-15
ATE551989T1 (de) 2012-04-15
DK1940351T3 (da) 2012-07-02
CA2624088A1 (en) 2007-04-12
JP2014012712A (ja) 2014-01-23

Similar Documents

Publication Publication Date Title
IL190499A0 (en) Sustained release small molecule drug formulation
IL188964A0 (en) Sustained drug release composition
ZA200705530B (en) Sustained release pharmaceutical formulations
IL191907A0 (en) Azepinoindole derivatives as pharmaceutical agents
PL2034970T3 (pl) Preparat farmaceutyczny o przedłużonym uwalnianiu zawierający fenylefrynę
ZA200710734B (en) Compositions for drug delivery
EP2119442A4 (en) PHARMACEUTICAL COMPOSITION WITH TACROLIMUS MAINTAINED RELEASE
IL217841A0 (en) Long lasting drug formulations
IL184558A0 (en) Sustained release composition of protein drug
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
GB0614586D0 (en) Pharmaceutical Formulation
GB0526419D0 (en) Formulation
GB0517673D0 (en) Formulation
EP1753405A4 (en) SLOW RELEASE PHARMACEUTICAL PREPARATION
IL198160A0 (en) Pharmaceutical formulations
EP1871348A4 (en) PHARMACEUTICAL COMPOSITIONS WITH DELAYED RELEASE
GB0406048D0 (en) Drug formulations
GB0501030D0 (en) Formulation
ZA200706807B (en) Composition containing chitosan for sustained drug release
TWI372053B (en) Combination drug
ZA200801158B (en) Sustained drug release composition
GB0515937D0 (en) Pharmaceutical formulation
AU2005904737A0 (en) Drug formulation
GB0417042D0 (en) Stable pharmaceutical formulation
GB0514530D0 (en) Pharmaceutical agent